Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

States Modify PSE Rx-Only Proposals To Curb Meth Production

This article was originally published in The Tan Sheet

Executive Summary

Legislators in Kentucky debate requiring a prescription for purchase of OTC pseudoephedrine over monthly and annual limits, while Oklahoma lawmakers consider requiring pharmacists to determine a patient’s need. CHPA opposes further limits on access and promotes electronic tracking with stop-sale technology.

You may also be interested in...



NPLEx Pays Dividends In Stopping Multi-State PSE Purchases

The largest amount of NPLEx-stopped sales was in Texas – 209,000 grams or 82,000 boxes. “People who don’t know the tracking system is in effect are still trying to purchase over the legal limit across state lines,” says National Association of Drug Diversion Investigators Executive Director Charles Cichon.

NPLEx Pays Dividends In Stopping Multi-State PSE Purchases

The largest amount of NPLEx-stopped sales was in Texas – 209,000 grams or 82,000 boxes. “People who don’t know the tracking system is in effect are still trying to purchase over the legal limit across state lines,” says National Association of Drug Diversion Investigators Executive Director Charles Cichon.

FDA Execs Prefer Novel Switch Model Sans Intervention

Leaders at FDA’s drug center appear more closely aligned with the OTC industry than with medical professionals’ groups on consumer access to innovative switches. CDER Director Woodcock says the clinical community has resisted switches – and been proven wrong – before.

Related Content

Topics

UsernamePublicRestriction

Register

PS105601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel